Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 6/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25769806 | 0.91 | BCHE (0.52) | BCHETK1ALBPKMLMNA | |
| SCHEMBL23032327 | 0.91 | BCHE (0.52) | BCHETK1ALBPKMLMNA | |
| SCHEMBL27270377 | 0.91 | BCHE (0.52) | BCHETK1ALBPKMLMNA | |
| SCHEMBL25061417 | 0.91 | BCHE (0.52) | BCHETK1ALBPKMLMNA | |
| SCHEMBL1887624 | 0.89 | BCHE (0.51) | BCHETK1ALBPKMLMNA | |
| SCHEMBL24787955 | 0.85 | BCHE (0.50) | BCHETK1ALBPKM | |
| SCHEMBL24370767 | 0.85 | BCHE (0.48) | BCHETK1ALBPKMLMNA | |
| SCHEMBL6526270 | 0.85 | BCHE (0.48) | BCHETK1ALBPKMLMNA | |
| SCHEMBL27364588 | 0.85 | BCHE (0.48) | BCHETK1ALBPKMLMNA | |
| SCHEMBL26316126 | 0.85 | BCHE (0.48) | BCHETK1ALBPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054720-A1 | Antisense Oligonucleotides Targeting ATXN3 | HOFFMANN-LA ROCHE INC. | 2023-02-23 | — | — | US | disclosed |
| US-20220204973-A1 | Antisense Oligonucleotide for Targeting Progranulin | HOFFMANN LA ROCHE (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220031730-A1 | ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION | HOFFMANN-LA ROCHE INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11066669-B2 | Oligonucleotides for modulating ATXN2 expression | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200024600-A1 | OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION | HOFFMANN-LA ROCHE INC. | 2020-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031730-A1 | ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION | FUBP1, FUBP3, IGF2BP1 | BCHE 3374/4885TK1 371/4885ALB 3340/4885 |
| US-20230054720-A1 | Antisense Oligonucleotides Targeting ATXN3 | ATXN2, ATXN2L, ATXN10 | BCHE 3655/4885TK1 891/4885ALB 4130/4885 |
| US-11066669-B2 | Oligonucleotides for modulating ATXN2 expression | ATXN2, ATXN2L, ATXN10 | BCHE 1495/4885TK1 1678/4885ALB 4043/4885 |
| US-20200024600-A1 | OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATXN10 | BCHE 1495/4885TK1 1678/4885ALB 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.